Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31230985 | 0.79 | EGFR (0.34) | SMN1; SMN2 | |
| SCHEMBL25364239 | 0.79 | EGFR (0.34) | SMN1; SMN2 | |
| SCHEMBL31344845 | 0.77 | XDH (0.33) | PARP1XDHSLC22A12 | |
| SCHEMBL8186519 | 0.68 | XDH (0.34) | PARP1XDHSLC22A12SMN1; SMN2 | |
| SCHEMBL25689257 | 0.67 | TRPV4 (0.35) | — | |
| SCHEMBL25368164 | 0.66 | — | — | |
| SCHEMBL25365858 | 0.66 | NR3C2 (0.35) | PARP1SMN1; SMN2 | |
| SCHEMBL31231017 | 0.66 | — | — | |
| SCHEMBL29915085 | 0.66 | PDE4A (0.31) | — | |
| SCHEMBL27002580 | 0.66 | PDE4A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177408-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Etern Therapeutics Hongkong Limited (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4484420-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023155927-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海奕拓医药科技有限责任公司 | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177408-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | YAP1, YES1, TEAD2 | PARP1 3652/4885XDH 927/4885SLC22A12 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.